Cocrystal Pharma, Inc. COCP Cash Flow

Cocrystal pharma, inc. (COCP)

CashFlow / Quarterly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11
Operating activities:
Net income (loss)
-1,990	-47,845	-1,780	-1,515	2,971	-44,286	-1,865	-1,344	-1,553	5,197	-2,259	-1,003	-2,548	-65,754	-1,881	-3,227	-4,012	-	-	-	-	-	-	-	-	-	-	-	-	-	-98	-714	-3,646	-1,845	-2,499	-1,098	-13
Net loss
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-508	-2,623	-16,542	-	-2,549	4,729	-372	-	-1,005	-1,030	-1,058	-	-	-	-	-	-	-	-
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Bad debt expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	50	40	9	301	9	9	7
Depreciation and amortization expense
30	29	24	22	23	10	11	14	15	24	25	26	26	42	50	53	56	-	-	-	-	-	-	-	-	-	-	-	-	-221	121	124	114	159	205	90	76
Amortization of right of use assets
44	-	-	-	43	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Depreciation
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	45	43	45	-	47	50	57	-	59	59	60	-	-	-	-	-	-	-	-
Stock-based compensation
107	98	107	113	33	230	120	107	105	205	141	56	212	251	-1,139	717	719	885	738	1,218	93	13	5	9	11	12	12	13	18	-	-	-	-	-	-	-	-
Interest expense, net
-	-	-	-	-	3	0	23	32	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payments on operating lease liabilities
44	39	41	26	27	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change in deferred income tax
-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Fair value of warrant liabilities in excess of proceeds from financing
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-
Amortization of financing costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	14	17	1	1	160	0	-6	6
Change in fair value of derivative liabilities
-27	83	33	40	100	-104	129	260	21	286	-148	198	571	430	-38	938	1,273	-	-	-	-	-	-	-	-	-	-	0	0	-324	21	37	418	-281	0	0	0
Gain on settlement of mortgage note receivable
-	-	-	-	-	0	0	0	106	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred income tax benefit
-	-	-	-	-	-	-	-554	-419	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Fair value of warrant liabilities in excess of proceeds from financing
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	946	-	-	-	-	-	-	-	-	-	-	-	-
Change in fair value of derivative liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-3,034	-2,890	14,418	-	792	-5,638	-2,106	-	-	-	-	-	-	-	-	-	-	-	-
Change in deferred rent
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-2	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest expense related to warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Equity interest in subsidiary
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6
Non-cash interest expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	439	427	955	3,359	758	0	-1	1
Changes in operating assets and liabilities:
Accounts receivable
-	-124	-146	-164	1,078	-	-	-	-	-	-	-	-21	5	-35	35	-16	-	-	-	-	-	-	-	-	-	-	-	-	-	242	-265	-522	991	-163	-273	6
Inventories
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	251	-629	78	125	-549	188	-430
Prepaid expenses and other current assets
33	-32	106	-74	-22	-87	49	26	98	-136	65	-76	-266	-108	431	-234	-13	-	-	-	-	-	-	-	-	-	-	-	-	-	65	-180	-235	-85	34	-53	2
Deposits
11	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accounts payable and accrued expenses
-340	306	329	150	134	99	213	-45	-27	-57	-192	-28	558	-680	-271	-1,570	499	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest income
-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gain on mortgage note receivable
-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred rent
-	-	0	0	3	7	7	8	6	-	-	-7	16	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Prepaid expenses and other current assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-272	-43	-72	-	40	-4	-10	-	-2	14	27	-	-	-	-	-	-	-	-
Accounts payable and accrued expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	164	-27	-499	-	46	6	306	-	78	-34	1	-	-	-	-	-	-	-	-
Deferred taxes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	7
Accounts payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-549	437	-446	-1,101	1,282	741	-270
Accrued expenses and other current liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	203	-100	46	-230	338	541	30	137
Net cash used in operating activities - continuing operations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1,085	400	-102	-1,935	-379	809	-388	-462
Net cash (used in) provided by operating activities
-2,188	-1,230	-1,323	-1,028	2,018	-1,970	-2,149	-2,093	-2,078	-1,580	-2,186	-1,085	-2,052	-2,301	-3,146	-5,166	-4,042	-3,040	-3,187	-2,531	-1,559	-1,755	-1,139	-1,338	-1,780	-808	-948	-978	-952	-	-	-	-	-	-	-	-
Investing activities:
Cash acquired in acquisition of Biozone Pharmaceuticals, Inc.
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	589	-	-	-	-	-	-	-	0	-	-	-	-
Purchases of property and equipment
93	1	115	4	25	15	8	0	5	0	0	7	33	2	13	18	18	122	199	13	5	1	4	0	0	-	-	-	-	-167	42	35	242	417	148	-15	24
Capital expenditures
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-
Cash acquired in reverse merger with Biozone Pharmaceuticals, Inc.
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-
Long-term deposits
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-9	-1	13	0	0	0	0	-	-	-	-	-	-	-	-
Proceeds from settlement of mortgage note receivable
-	-	-	-	-	0	0	0	1,400	0	0	0	0	-	-	-	-	-55	18	18	19	-8	8	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Principal payments received on mortgage note receivable
-	-	-	-	-	-	-	-	-	-	-	-	-	19	-32	11	-19	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in investing activities
-93	-1	-115	-4	-25	-15	-8	0	1,395	12	0	-19	-33	35	21	-54	1	-100	-181	5	14	2,718	13	2,775	576	-3	-1	0	0	167	-42	-35	-242	-417	-148	601	-24
Financing activities:
Payments on finance lease liabilities
57	55	42	65	52	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Borrowings from noteholders
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	406
Repayment of borrowings from noteholders
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	100	375	63	2,111	2,725	0	-29	29
Payment of deferred financing costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	150
Proceeds from sale of common stock, net of transaction costs
16,606	-	-	0	3,928	-	-	-	-	-	-	-	-	0	4,009	0	5,004	0	0	4,050	11,812	-	0	0	2,750	-	0	0	0	0	0	0	650	705	0	0	0
Proceeds from issuance of convertible notes
-	-	-	-	-	0	0	0	1,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	450	3,300	500	0	0	2,250
Proceeds from issuance of notes payable
-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from issuance of Series A preferred stock, net of issuance costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-
Proceeds from issuance of common stock and options to Teva, net of issuance costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-
Proceeds from exercise of stock options
-	-	-	-	-	43	0	1	184	0	80	0	0	0	0	0	3	3	0	0	20	1	58	38	19	2	0	1	4	-	-	-	-	-	-	-	-
Payment to shareholder
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1
Net cash provided by financing activities
16,549	2,655	-42	-65	3,876	24	0	7,685	1,184	1,000	80	3,000	0	0	4,009	0	5,007	3	0	4,050	11,832	1	58	38	2,769	2	0	1	4	90	-450	234	1,838	432	-1,719	-613	2,475
Net increase in cash and restricted cash
14,268	1,424	-1,480	-1,097	5,869	-1,961	-2,157	5,592	501	-568	-2,106	1,896	-2,085	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
SUPPLEMENTAL DISCLOSURE OF NON-CASH OPERATING ACTIVITIES:
Recognition of operating lease right-of-use assets and operating lease liabilities upon adoption of ASC Topic 842, Leases
-	0	0	0	833	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net decrease in cash and cash equivalents
-	-	-	-	-	-	-	-	-	-	-	-	-	-	884	-5,220	966	-	-3,368	1,524	10,287	964	-1,068	1,475	1,565	-809	-949	-977	-948	306	-91	97	-339	-365	-1,057	-399	1,988
Unrealized loss on marketable securities net of tax
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	744	-980	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cashless exercise of warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	35	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Prepaid expenses and other current assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	3	-	-	-	-	-	-	-	-	-	-	-	-
Marketable securities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	74	8,737	-	-	-	-	-	-	-	-	-	-	-	-
Accounts payable and accrued expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	410	-	-	-	-	-	-	-	-	-	-	-	-
Unrealized gain (loss) on marketable securities net of tax
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3,278	-1,451	-	-	-	-	-	-	-	-	-	-	-	-
Estimated fair value of warrants exchanged for common shares
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	9,426	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Cashless exercise of warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Derivative liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	10,475	-	-	-	-	-	-	-	-	-	-	-	-
Interest paid
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-55	55	32	223	219	101	110	107